Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Androgens and anabolic steroids
Plomestane
Другие языки:

    Plomestane

    Подписчиков: 0, рейтинг: 0
    Plomestane
    Plomestane.svg
    Clinical data
    Other names MDL-18962; Propargylestrenedione; PED; 10-(2-Propyn-1-yl)estr-4-ene-3,17-dione; 10-Propargylestr-4-ene-3,17-dione
    ATC code
    • None
    Identifiers
    • 10H-(2-Propynyl)-estr-4-ene-3,17-dione
    CAS Number
    PubChem CID
    ChemSpider
    UNII
    Chemical and physical data
    Formula C21H26O2
    Molar mass 310.437 g·mol−1
    3D model (JSmol)
    • O=C4\C=C3/[C@@](CC#C)([C@H]2CC[C@@]1(C(=O)CC[C@H]1[C@@H]2CC3)C)CC4
    • InChI=1S/C21H26O2/c1-3-10-21-12-8-15(22)13-14(21)4-5-16-17-6-7-19(23)20(17,2)11-9-18(16)21/h1,13,16-18H,4-12H2,2H3/t16-,17-,18-,20-,21-/m0/s1
    • Key:JKPDEYAOCSQBSZ-OEUJLIAZSA-N

    Plomestane (INN, USAN; former developmental code name MDL-18962; also known as propargylestrenedione, PED) is a steroidal, irreversible aromatase inhibitor which was under development by Marion Merrell Dow/Hoechst Marion Russell (now Hoechst AG) as an antineoplastic agent for the treatment of breast cancer. It was found to be effective in preclinical studies and was also found to produce few adverse effects in human clinical trials, significantly reducing estrogen levels with a single administration. However, development of the drug for clinical use was halted due to "technical issues" and it was never marketed.

    In addition to its activity as an aromatase inhibitor, plomestane has weak androgenic properties.

    See also




    Новое сообщение